IQVIA Holdings Inc. $IQV Shares Sold by Federated Hermes Inc.

Federated Hermes Inc. decreased its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV) by 39.9% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 73,511 shares of the medical research company’s stock after selling 48,749 shares during the period. Federated Hermes Inc.’s holdings in IQVIA were worth $13,963,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also made changes to their positions in the business. Brighton Jones LLC increased its holdings in shares of IQVIA by 244.4% in the fourth quarter. Brighton Jones LLC now owns 3,575 shares of the medical research company’s stock valued at $703,000 after buying an additional 2,537 shares in the last quarter. Empowered Funds LLC raised its position in shares of IQVIA by 102.1% during the first quarter. Empowered Funds LLC now owns 9,728 shares of the medical research company’s stock worth $1,715,000 after purchasing an additional 4,915 shares during the period. Sivia Capital Partners LLC purchased a new stake in shares of IQVIA during the second quarter valued at $514,000. Farther Finance Advisors LLC boosted its position in shares of IQVIA by 34.0% in the 2nd quarter. Farther Finance Advisors LLC now owns 398 shares of the medical research company’s stock valued at $63,000 after purchasing an additional 101 shares during the period. Finally, Truist Financial Corp increased its stake in IQVIA by 8.4% in the 2nd quarter. Truist Financial Corp now owns 159,707 shares of the medical research company’s stock worth $25,168,000 after purchasing an additional 12,424 shares in the last quarter. 89.62% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on IQV. Truist Financial lifted their target price on shares of IQVIA from $265.00 to $290.00 and gave the stock a “buy” rating in a research report on Thursday, January 8th. JPMorgan Chase & Co. lifted their price target on IQVIA from $177.00 to $255.00 and gave the company an “overweight” rating in a report on Wednesday, October 29th. Weiss Ratings restated a “hold (c)” rating on shares of IQVIA in a research report on Thursday, January 22nd. Morgan Stanley upped their target price on IQVIA from $250.00 to $265.00 and gave the company an “overweight” rating in a report on Monday, December 1st. Finally, Citigroup raised their price target on shares of IQVIA from $200.00 to $230.00 and gave the stock a “neutral” rating in a report on Wednesday, October 29th. Two equities research analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and five have issued a Hold rating to the company’s stock. According to data from MarketBeat, IQVIA has an average rating of “Moderate Buy” and an average target price of $251.06.

IQVIA Stock Performance

Shares of IQV opened at $229.93 on Friday. The company has a debt-to-equity ratio of 2.03, a current ratio of 0.70 and a quick ratio of 0.70. IQVIA Holdings Inc. has a one year low of $134.65 and a one year high of $247.04. The company’s fifty day moving average price is $230.94 and its 200 day moving average price is $208.54. The company has a market capitalization of $39.16 billion, a PE ratio of 31.54, a price-to-earnings-growth ratio of 2.39 and a beta of 1.36.

IQVIA Company Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.